Therapeutic use of citrulline in cardiovascular disease.

Therapeutic use of citrulline in cardiovascular disease. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Therapeutic use of citrulline in cardiovascular disease. Abstract Text:

Maritza J Romero,Daniel H Platt,Ruth B Caldwell,R William Caldwell,

L-citrulline is the natural precursor of L-arginine, substrate for nitric oxide synthase (NOS) in the production of NO. Supplemental administration L-arginine has been shown to be effective in improving NO production and cardiovascular function in cardiovascular diseases associated with endothelial dysfunction, such as hypertension, heart failure, atherosclerosis, diabetic vascular disease and ischemia-reperfusion injury, but the beneficial actions do not endure with chronic therapy. Substantial intestinal and hepatic metabolism of L-arginine to ornithine and urea by arginase makes oral delivery very ineffective. Additionally, all of these disease states as well as supplemental L-arginine enhance arginase expression and activity, thus reducing the effectiveness of L-arginine therapy. In contrast, L-citrulline is not metabolized in the intestine or liver and does not induce tissue arginase, but rather inhibits its activity. L-citrulline entering the kidney, vascular endothelium and other tissues can be readily converted to L-arginine, thus raising plasma and tissue levels of L-arginine and enhancing NO production. Supplemental L-citrulline has promise as a therapeutic adjunct in disease states associated with L-arginine deficiencies.

Therapeutic use of citrulline in cardiovascular disease. Publishing Authors By Initials

MJ Romero,DH Platt,RB Caldwell,RW Caldwell,

For similar cells: muscle cells: myocytes, smooth muscle research abstracts see: cells: muscle cells: myocytes, smooth muscle research

PUBMED ID PMID:

MEDLINE DATE: 2006 Fall-Winte

Therapeutic use of citrulline in cardiovascular disease. Journal Published:

PUBLICATION TYPE: Review

Journal: Cardiovascular drug reviews

VOLUME: 24

Page Numbers: 275-90

Journal Abbreviation:

ISSN: 0897-5957

DAY: 3

MONTH: 12

YEAR: 2007

Therapeutic use of citrulline in cardiovascular disease. Information

Number of References: 107

LANGUAGE: eng

NlmUniqueID: 9006912

Therapeutic use of citrulline in cardiovascular disease. Keywords Mesh Terms:

KEYWORDS: Myocytes, Smooth Muscle

MESH TERMS: metabolism

Chemical & Substance for Abstract: Therapeutic use of citrulline in cardiovascular disease. Information

Substance Name: Arginine

Registry Number: 74-79-3

Grant and Affiliation Information for Therapeutic use of citrulline in cardiovascular disease.

AFFILIATION: Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta GA, USA.

Country: United States

AGENCY: United States NHLBI

GRANT: R01-HL070215

ACRONYM: HL

MEDLINETA: Cardiovasc Drug Rev

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Therapeutic use of citrulline in cardiovascular disease Related Publications

• A mobile phone-based Communication Support System for elderly persons.
• A new infusion pathway intactness monitoring system.
• A new venous infusion pathway monitoring system.
• A population study of neutering status as a risk factor for canine prostate cancer.
• Adsorption and viscoelastic properties of fractionated mucin (BSM) and bovine serum albumin (BSA) studied with quartz crystal microbalance (QCM-D).
• Biotechnological approach to the synthesis of 9alpha-hydroxylated steroids.
• Chlamydia trachomatis species-specific induction of ezrin tyrosine phosphorylation functions in pathogen entry.
• CpG islands: their potential as biomarkers for cancer.
• Current developments and problems in military neuropsychiatry.
• Deterioration of academic achievement and marijuana use onset among rural adolescents.
• Effect of reconstruction algorithms on myocardial blood flow measurement with 13N-ammonia PET.
• Expression of corticosteroid binding globulin in the rat central nervous system.
• Fatigue in aviation.
• Homocysteine induces endothelial dysfunction via inhibition of arginine transport.
• Improving practice--the Hospital Pharmacy Initiative revisited.
• Neighborhood residence and cigarette smoking among urban youths: the protective role of prosocial activities.
• Neurodegeneration and cell replacement.
• Olfactory bulb hypoplasia in Prokr2 null mice stems from defective neuronal progenitor migration and differentiation.
• Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen.
• Particulate platform for bioluminescent immunosensing.
• Peroxynitrite mediates VEGF's angiogenic signal and function via a nitration-independent mechanism in endothelial cells.
• Phenotypic rescue of Chlamydia trachomatis growth in IFN-gamma treated mouse cells by irradiated Chlamydia muridarum.
• Problems of the small community hospital.
• Protection against myocardial ischemia/reperfusion injury by short-term diabetes: enhancement of VEGF formation, capillary density, and activation of cell survival signaling.
• Sources of folate and serum folate levels in older adults.
• The PAPM, diffusion theory, and violent death surveillance.
• The impact of SCHIP enrollment on adolescent-provider communication.
• Therapeutic use of citrulline in cardiovascular disease.
• Use of an immediate, qualitative progesterone assay for determination of day of ovulation in an equine embryo transfer program.
• Vitamin requirements in patients receiving total parenteral nutrition (TPN).